The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
ONLY
ARTICLE
November 10, 2014
Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia (online only)
Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
Obinutuzumab (Gazyva) for Chronic Lymphocytic Leukemia (online only)
November 10, 2014 (Issue: 1455)
Obinutuzumab (Gazyva – Genentech), a humanized anti-CD20 monoclonal
antibody, has been approved by the FDA for use in
combination with chlorambucil (Leukeran) in patients
with previously untreated chronic lymphocytic
leukemia (CLL). Two other...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.